Recent Advances in Angiogenesis and Antiangiogenesis

Indexed in: Scopus, EBSCO.

The book presents recent advances in the field of angiogenesis and antiangiogenesis. Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Inhibitors of Angiogenesis Based on Thrombospondin-1

Pp. 112-126 (15)

Giulia Taraboletti and Katiuscia Bonezzi


Angiogenesis-driven pathologies, including cancer, are sustained by a preponderance of angiogenic factors over endogenous inhibitors of new-vessel formation. Restoring this balance represents a logical therapeutic strategy to treat these pathologies. Therefore, endogenous inhibitors of angiogenesis, and in particular thrombospondin-1 (TSP-1), are a powerful source of potential antiangiogenic tools. Different therapeutic approaches have been proposed to exploit the antiangiogenic properties of TSP-1, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies and agents that up-regulate TSP-1 expression. This review focuses on the possibility of exploiting TSP-1 for the design of antiangiogenic agents, with particular reference on their use in antineoplastic therapies.


Tumor Angiogenesis Unit, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo, Italy